205 related articles for article (PubMed ID: 24008662)
1. A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer.
Kruczek K; Ratterman M; Tolzien K; Sulo S; Lestingi TM; Nabhan C
Br J Cancer; 2013 Oct; 109(7):1711-6. PubMed ID: 24008662
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.
Armstrong AJ; Shen T; Halabi S; Kemeny G; Bitting RL; Kartcheske P; Embree E; Morris K; Winters C; Jaffe T; Fleming M; George DJ
Clin Genitourin Cancer; 2013 Dec; 11(4):397-406. PubMed ID: 23830964
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer.
Barata PC; Cooney M; Mendiratta P; Gupta R; Dreicer R; Garcia JA
Invest New Drugs; 2019 Apr; 37(2):331-337. PubMed ID: 30402678
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).
Templeton AJ; Dutoit V; Cathomas R; Rothermundt C; Bärtschi D; Dröge C; Gautschi O; Borner M; Fechter E; Stenner F; Winterhalder R; Müller B; Schiess R; Wild PJ; Rüschoff JH; Thalmann G; Dietrich PY; Aebersold R; Klingbiel D; Gillessen S;
Eur Urol; 2013 Jul; 64(1):150-8. PubMed ID: 23582881
[TBL] [Abstract][Full Text] [Related]
5. Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer.
Emmenegger U; Booth CM; Berry S; Sridhar SS; Winquist E; Bandali N; Chow A; Lee C; Xu P; Man S; Kerbel RS; Ko YJ
Oncologist; 2015 Dec; 20(12):1351-2. PubMed ID: 26542984
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.
Oza AM; Elit L; Tsao MS; Kamel-Reid S; Biagi J; Provencher DM; Gotlieb WH; Hoskins PJ; Ghatage P; Tonkin KS; Mackay HJ; Mazurka J; Sederias J; Ivy P; Dancey JE; Eisenhauer EA
J Clin Oncol; 2011 Aug; 29(24):3278-85. PubMed ID: 21788564
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer.
Nakabayashi M; Werner L; Courtney KD; Buckle G; Oh WK; Bubley GJ; Hayes JH; Weckstein D; Elfiky A; Sims DM; Kantoff PW; Taplin ME
BJU Int; 2012 Dec; 110(11):1729-35. PubMed ID: 22928480
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study.
Nabhan C; Patel A; Villines D; Tolzien K; Kelby SK; Lestingi TM
Clin Genitourin Cancer; 2014 Feb; 12(1):27-32. PubMed ID: 24238760
[TBL] [Abstract][Full Text] [Related]
9. A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer.
McHugh DJ; Chudow J; DeNunzio M; Slovin SF; Danila DC; Morris MJ; Scher HI; Rathkopf DE
Clin Genitourin Cancer; 2020 Jun; 18(3):171-178.e2. PubMed ID: 32057715
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer.
Pulido M; Roubaud G; Cazeau AL; Mahammedi H; Vedrine L; Joly F; Mourey L; Pfister C; Goberna A; Lortal B; Bellera C; Pourquier P; Houédé N
BMC Cancer; 2018 Feb; 18(1):194. PubMed ID: 29454321
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199).
Tinker AV; Ellard S; Welch S; Moens F; Allo G; Tsao MS; Squire J; Tu D; Eisenhauer EA; MacKay H
Gynecol Oncol; 2013 Aug; 130(2):269-74. PubMed ID: 23672928
[TBL] [Abstract][Full Text] [Related]
12. Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer.
Amato RJ; Wilding G; Bubley G; Loewy J; Haluska F; Gross ME
Clin Genitourin Cancer; 2012 Dec; 10(4):232-8. PubMed ID: 22695254
[TBL] [Abstract][Full Text] [Related]
13. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.
Hess G; Herbrecht R; Romaguera J; Verhoef G; Crump M; Gisselbrecht C; Laurell A; Offner F; Strahs A; Berkenblit A; Hanushevsky O; Clancy J; Hewes B; Moore L; Coiffier B
J Clin Oncol; 2009 Aug; 27(23):3822-9. PubMed ID: 19581539
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.
Kyriakopoulos CE; Braden AM; Kolesar JM; Eickhoff JC; Bailey HH; Heideman J; Liu G; Wisinski KB
Invest New Drugs; 2017 Jun; 35(3):290-297. PubMed ID: 28004284
[TBL] [Abstract][Full Text] [Related]
15. Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors.
Weikert S; Kempkensteffen C; Busch J; Johannsen M; Grünwald V; Zimmermann K; Flörcken A; Westermann J; Weinkauf L; Miller K; Keilholz U
World J Urol; 2013 Aug; 31(4):805-9. PubMed ID: 21512806
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies.
Trivedi ND; Armstrong S; Wang H; Hartley M; Deeken J; Ruth He A; Subramaniam D; Melville H; Albanese C; Marshall JL; Hwang J; Pishvaian MJ
Cancer Med; 2021 Mar; 10(6):1944-1954. PubMed ID: 33638305
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.
Galanis E; Buckner JC; Maurer MJ; Kreisberg JI; Ballman K; Boni J; Peralba JM; Jenkins RB; Dakhil SR; Morton RF; Jaeckle KA; Scheithauer BW; Dancey J; Hidalgo M; Walsh DJ;
J Clin Oncol; 2005 Aug; 23(23):5294-304. PubMed ID: 15998902
[TBL] [Abstract][Full Text] [Related]
18. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo J; Trandafir L; Wagner V; Li R; Nordquist LT
Prostate; 2019 Oct; 79(14):1683-1691. PubMed ID: 31442327
[TBL] [Abstract][Full Text] [Related]
19. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.
Smith SM; van Besien K; Karrison T; Dancey J; McLaughlin P; Younes A; Smith S; Stiff P; Lester E; Modi S; Doyle LA; Vokes EE; Pro B
J Clin Oncol; 2010 Nov; 28(31):4740-6. PubMed ID: 20837940
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma.
Sun Y; Rha S; Lee SH; Guo J; Ueda T; Qin S; Naito S; Cincotta M; Tokushige K; Akaza H
Jpn J Clin Oncol; 2012 Sep; 42(9):836-44. PubMed ID: 22844126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
